

## A Mini Review on A $\beta$ Oligomers and its Pathogenicity

Pham Thi Dieu Tuyet<sup>†</sup>

### Abstract

Amyloid oligomers are believed to play important causal roles in many types of amyloid-related degenerative diseases. Many different laboratories have reported amyloid oligomers that differ in size, morphology, toxicity, and method of preparation or purification, raising the question of the structural relationships among these oligomer preparations. The structural plasticity that has been reported to occur in amyloid formed from the same protein sequence indicates that it is quite possible that different oligomer preparations may represent distinct structural variants. In view of the difficulty in determining the precise structure of amyloids, conformation- and epitope-specific antibodies may provide a facile means of classifying amyloid oligomer structures. Conformation-dependent antibodies that recognize generic epitopes that are specifically associated with distinct aggregation states of many different amyloid-forming sequences indicate that there are at least two fundamentally distinct types of amyloid oligomers: fibrillar and prefibrillar oligomers. Classification of amyloid oligomers according to their underlying structures may be a more useful and rational approach than relying on differences in size and morphology.

**Key words:** A $\beta$ , Monomers, Fibrils, Oligomers, Alzheimer's Disease

### 1. Introduction

A number of age-related degenerative diseases are characterized by the accumulation of misfolded proteins as amyloid deposits. Amyloid deposits are typically composed of 6-10 nm “cross- $\beta$ -fibrils, in which the polypeptide chain is arranged in  $\beta$ -sheets where the polypeptide is perpendicular to the fibril axis and hydrogen bonding is parallel<sup>[1]</sup>. In AD, several types of amyloid deposits containing the A $\beta$  peptide accumulate, including diffuse amyloid deposits, “cored,” “neuritis,” and “compact or burned out” senile plaques<sup>[2]</sup>, and cerebrovascular amyloid deposits. The linkage of familial AD mutations to the increased production of more highly aggregation-prone A $\beta$ 42 supports a causal role of A $\beta$  aggregation in disease<sup>[3]</sup>, but the precise relationships between aggregation state and disease remain to be established. Many other age-related degenerative diseases are also characterized by the accumulation of amyloid deposits derived from a

variety of other proteins. The hallmark lesions of Parkinson disease involve the accumulation of  $\beta$ -synuclein, whereas Huntington and other CAG triplet diseases are typified by the accumulation of polyglutamine-containing aggregates. This also includes prion diseases such as Creutzfeldt-Jakob disease with accumulation of misfolded prion protein, type II diabetes with accumulation of islet amyloid polypeptide, and amyotrophic lateral sclerosis with aggregated superoxide dismutase-1. Like AD, many of these diseases have both a sporadic and inherited form, and in many cases, the mutations associated with the familial forms are in the gene encoding the protein that accumulates or in genes directly related to its production, processing, or accumulation. Although these diseases are associated with different proteins of widely varying normal structure and function, they all involve the accumulation of abnormal aggregates containing  $\beta$ -sheet structure.

There is conflicting evidence for the role of macroscopic fibrillar amyloid deposits in pathogenesis. It has been reported that the extent of amyloid plaque accumulation does not correlate well with AD pathogenesis<sup>[4]</sup> and that a significant number of non-demented individuals have significant amounts of amyloid plaques. In some transgenic animal and cell culture

Department of Biotechnology, Hanoi University of Science and Technology, University of Hanoi, Vietnam.


<sup>†</sup>Corresponding author : [phamtuyet0585@gmail.com](mailto:phamtuyet0585@gmail.com)  
(Received : June 2, 2014, Revised : June 13, 2014,  
Accepted : June 25, 2014)

models, pathological changes are frequently observed prior to the onset of amyloid plaque accumulation<sup>[5,6]</sup>. It has also been reported that soluble A $\beta$  correlates better with dementia than insoluble fibrillar deposits<sup>[7,8]</sup>, suggesting that oligomeric forms of A $\beta$  may represent the primary toxic species in AD. Indeed, soluble prefibrillar oligomers have been implicated as primary causative agents in many different degenerative diseases in which the accumulation of large fibrillar deposits may be either inert or protective<sup>[9,10]</sup>. For A $\beta$ , aggregates ranging from dimers up to particles of one Million Da or greater have been reported *in vitro*<sup>[11-16]</sup>. Electron microscopy and atomic force microscopy have identified spherical particles of  $\beta$ 3-10 nm that appear at early times of incubation and disappear as mature fibrils appear<sup>[16-18]</sup>. These spherical oligomers appear to represent intermediates in the pathway of fibril formation because they are transiently observed at intermediate times of incubation during fibril formation. Soluble A $\beta$  oligomers have been referred to as amorphous aggregates, micelles, protofibrils, prefibrillar aggregates, ADDLs, A $\beta$ \*56, globulomers, amylo-spheroids, “tA $\beta$ ” (toxic soluble A $\beta$ ), “paranuclei,” and annular protofibrils<sup>[11,13,15-17,19-26]</sup>. A similar spectrum of soluble oligomers has been observed for many types of amyloids such as  $\beta$ -synuclein<sup>[27]</sup>, islet amyloid<sup>[28]</sup>, and non-disease-associated “neoamyloids”<sup>[21]</sup>. Although these oligomers have been formed under different conditions and display different toxic activities, sizes, and morphologies, it is not yet clear whether they represent the same or distinct structures.

## 2. Different Classes of Amyloid Oligomers

If the structures of these amyloid oligomers were known, it would be obvious what their relationships are and how many different and unique structures they represent. Only the structures of a few of the amyloid fibrils are known<sup>[29-33]</sup>, and many of these structures are not known at a resolution sufficient to evaluate how many structural variants exist. These structural studies have revealed that fibrils are composed of parallel, in-register, hydrogen-bonded peptide strands, and a recent x-ray crystallographic analysis of a large number fibrils formed by small, 6–7-residue peptides confirms that parallel in-register structure is a common motif and provides additional details of the fibril structures at

atomic resolution<sup>[34]</sup>. In the absence of high resolution oligomer structures, conformation-dependent antibodies can distinguish different types of amyloid structures. Conformation-dependent antibodies and antisera that specifically recognize amyloid fibrils<sup>[35-38]</sup> or prefibrillar oligomers (Fig. 1)<sup>[39]</sup> have been reported. Many of these antibodies are also interesting because they have the



**Fig. 1.** Schematic representation of various types of amyloid oligomers. The aggregation pathway begins with a misfolded amyloidogenic monomer (*top*) and can diverge into two paths depending on which conformation it adopts. Monomers can aggregate to form prefibrillar oligomers that are A11-positive and OC-negative (*left pathway*). These prefibrillar oligomers may then align to form protofibrils (not shown) and undergo a concerted conformation change “en bloc” to form fibrils. They are termed prefibrillar oligomers because they are transient intermediates that ultimately become fibrils. In the other pathway, amyloidogenic monomers aggregate to form a fibrillar conformation or lattice that is OC-positive and A11-negative (*right pathway*). These fibrillar oligomers may represent fibril nuclei or seeds that are aggregates capable of elongating by recruiting additional monomers at their ends. Addition of monomers ultimately elongates the fibrils to a size that satisfies an arbitrary definition of insolubility and would be recognized as fibrillar under the electron or atomic force microscope, although no conformational difference is apparent by antibody reactivity. This does not imply that a fundamental conformational change in their integral peptide-building blocks is necessary for fibrillar oligomers to convert to fibrils. They may simply coalesce or grow by monomer addition to form fibrils.

unusual property of recognizing generic epitopes that are associated with specific aggregation states regardless of their amino acid sequence. The fact that these epitopes are widely distributed yet distinct and non-overlapping between fibrils and prefibrillar oligomers suggests that there is a fundamental structural difference in the organization of the polypeptide backbone between these two classes of amyloid structures that is shared by many different types of amyloids. Although fibrils have often been operationally defined as insoluble material that sediments at 100,000 X g, the fact that small soluble oligomers also react with fibril-specific antibodies indicates that oligomers with the same type of structural organization as the insoluble fibril also exist (Fig. 1)<sup>[37]</sup>. Although fibrillar oligomers may sound like an oxymoron, the fact that fibril assembly is known to be a nucleation-dependent process indicates that the existence of these small “seed” aggregates, in which the peptide is organized in the same lattice structure of the fibrils, is to be expected.

### 3. Is There any Common Epitopes, and Do They Have Different Forms of Prefibrillar and Fibrillar Oligomers?

It is rather remarkable that the polyclonal immune response to fibrillar and prefibrillar amyloid antigens is largely independent of protein sequence and conformation-specific<sup>[37]</sup>. Why would an antibody raised against aggregates from one sequence recognize the same aggregation state of another protein sequence yet be conformationally specific for fibrillar or prefibrillar states? The structure of amyloid fibrils and oligomers may provide clues for the molecular basis for this peculiar specificity. Most of the fibril structures are relatively simple: parallel, in-register, intermolecularly hydrogen-bonded strands. This motif gives rise to side chain “steric zippers” composed of a single amino acid side chain that runs up and down the sheet<sup>[34,40]</sup>. These structures were first observed in  $\beta$ -helix proteins where a repeating sequence strand is interspersed with a helical spacer, giving rise to a parallel, in-register  $\beta$ -sheet that has stacks of identical amino acid side chains aligned up and down the sheet<sup>[41]</sup>. Because many amyloid fibril structures have these side chain zipper tracts and because specific amino acid side chains are widely

distributed among amyloid-forming sequences<sup>[42]</sup>, most fibrils would be expected to share these steric zippers, and they may constitute the fundamental structures recognized as generic epitopes. This hypothesis suggests that there are many different potential epitopes, at least one per side chain. If the epitope recognizes two adjacent zippers, the number of potential epitopes could be exponentially greater. Whether a given amyloid structure displays a particular steric zipper would depend on the primary sequence and folded structure of the  $\beta$ -sheet. Although steric zippers can explain the widespread generic nature of the epitopes, they do not explain why the antibodies distinguish between fibrillar and prefibrillar amyloid structures. The fact that the recognition of these generic structures by antibodies is distinct and mutually exclusive suggests that the difference is a fundamental difference in the organization of the peptide backbone. One possibility that has been suggested is that prefibrillar oligomers may be  $\beta$ -extended sheets<sup>[43]</sup>, whereas fibrillar structures are  $\beta$ -sheets. Another possibility is that the difference is due to differences in the twist, tilt, or hydrogen-bonding pattern of the individual  $\beta$ -strands within the sheet. Whether these hypothetical inferences are valid must await structural characterization of the prefibrillar oligomeric state.

### 4. So is the Size is Important?

For a long time, the aggregation state of amyloids has been judged by the solubility or the size of the oligomer according to sedimentation, size exclusion chromatography, and gel electrophoresis. Although this has been useful, size measurements may lack the structural resolution needed to distinguish alternative conformations and may not reflect the aggregation state under more physiological circumstances. On Western blots, A $\beta$  aggregates ranging from the size of a dimer all the way up to aggregates >500 kDa that stain with the fibril-specific antibody OC are observed (Fig. 1)<sup>[37]</sup>. In contrast, the prefibrillar oligomer-specific antibody A11 stains bands ranging from approximately tetrameric up to ~75 kDa (Fig. 1). Similar results were obtained for fibrillar oligomers under nondenaturing conditions, indicating that the small size of fibrillar oligomers is not an artifact of SDS-induced dissociation. The size distributions of soluble fibrillar and prefibrillar A $\beta$

oligomers broadly overlap, indicating that size is not a good indicator of their immunologically defined conformation and that distinct oligomeric conformations of the same size exist. If the oligomer structures are intermolecularly hydrogen-bonded extended structures as their  $\beta$ -sheet character would indicate, then the difference between a dimer and a trimer or a nonamer and a decamer would be no more significant than adding a single coin to the stack. Of course, size could matter for the activity of small oligomers in the 10-100 kDa range and those that are insoluble. Small oligomers would be expected to have a higher rate of diffusion, and if the growing ends of the  $\beta$ -sheets are important for pathogenesis, then small size provides a larger number of ends per unit mass of peptide.

### 5. Dose the Amyloid Aggregates Have Structural Polymorphisms within a Class?

In addition to prefibrillar oligomers and fibrils, structural variants or polymorphisms appear to exist within a class. This variation may be analogous to the well known phenomenon of strain variation in prions. Prion protein appears to be capable of forming aggregates that display subtle differences in their patterns of transmissibility and protease resistance<sup>[44]</sup>. Recent evidence indicates that structural variants also exist within A $\beta$  fibrils<sup>[45]</sup> and prefibrillar A $\beta$  oligomers<sup>[46]</sup>. For A $\beta$ , distinct fibril morphologies have subtle differences in the underlying structures determined by solid-state NMR. These distinct variants can be propagated by seeding the assembly of monomers<sup>[45]</sup>. For prefibrillar A $\beta$  oligomers, a polymorphism at the N-terminal 6E10 epitope that is displayed at low pH but hidden or absent at neutral pH was noted<sup>[46]</sup>. Yeast prion strains also display distinct conformations that arise by differences in the extent and overlap of the amyloid core region<sup>[47]</sup>. In human prions, variation in fibril structure that is detected by differences in antibody binding has been observed to occur in alternating fashion within a single amyloid fibril<sup>[48]</sup>. In view of the potential for structural heterogeneity within a fibril and the difficulty of determining the structure of amyloids, specific antibody binding may provide a more facile means of detecting and characterizing structural polymorphisms. The structural variability already reported in A $\beta$  and prion structures suggests that different amyloid oligomers

prepared under different conditions could have subtle differences in structure.

### 6. Amyloid Oligomers and its Structural Basis

Which oligomers are fibrillar or prefibrillar, and are there any other unique structures? Some data are beginning to emerge on which types of oligomers are formed *in vivo* and *in vitro*. ADDLs are formed *in vitro* by dissolving dry A $\beta$ 42 in Me<sub>2</sub>SO and diluting it in F12 cell culture medium to 100  $\mu$ M, followed by incubation at 4°C for 24 h<sup>[20]</sup>. ADDLs range in size from trimer and tetramer to approximately dodecamer *in vitro* and *in vivo*<sup>[49,50]</sup>. Although it is not yet clear whether ADDLs represent fibrillar or prefibrillar oligomers or some other unique type of aggregate, results with conformation-dependent anti-ADDL antibodies are consistent with ADDLs representing fibril-type oligomers because the antibodies stain plaques<sup>[51,52]</sup>. ADDLs bind preferentially to synapses on neurons<sup>[50,51]</sup>, and their level is elevated in AD brain<sup>[50]</sup> and cerebrospinal fluid<sup>[53]</sup>. Prefibrillar oligomers recognized by antibody A11 also occur in human AD brain, although they are only rarely associated with plaque deposits<sup>[39]</sup>. On Western blots, prefibrillar A $\beta$  oligomers range in size from approximately tetramers to ~20-mers<sup>[37]</sup>. A $\beta$ \*56 is a dodecamer that is correlated with cognitive deficits in transgenic animal models, and it is a prefibrillar type of oligomer because it stains with antibody A11 on Western blots<sup>[22]</sup>. Prefibrillar oligomers are also preferentially associated with axon terminals in AD and transgenic mouse brains<sup>[54,55]</sup>. Prefibrillar oligomers also bind preferentially to synapses on human neurons, suggesting that the conformational differences between fibrillar and prefibrillar oligomers are not important for synapse binding<sup>[56]</sup>. “Globulomers” are prepared *in vitro* by dissolving A $\beta$ 42 in hexafluoroisopropyl alcohol, drying, resuspending in Me<sub>2</sub>SO at a concentration of 5 mM, and diluting to 400  $\mu$ M in phosphate buffered saline containing 0.2% SDS. After incubation for 6 h at 37°C, the solution is diluted 3-fold with water and incubated for an additional 18 h at 37°C<sup>[23]</sup>. Globulomers run at ~38-48 kDa on SDS gels<sup>[23]</sup>. Globulomers bind in a punctuate distribution to neurons in an age-dependent fashion, and they alter synaptic activity<sup>[57]</sup>. Anti-globulomer conformation-dependent antibodies do

not react with monomeric A $\beta$  but stain fibrillar plaque deposits, suggesting that they are also specific for fibril-related epitopes. The reactivity of globulomers with fibril-specific antibodies suggests that they are fibril-type oligomers. The conformation of other types of A $\beta$  oligomers is not yet known, but it should be relatively easy to determine their status using the conformation-dependent antibodies that are currently available.

Original secreted A $\beta$  oligomers that run predominantly as dimers and trimers on SDS gels have been shown to inhibit long-term potentiation *in vitro*, but the conformation of these low molecular mass oligomers is not yet clear<sup>[58-60]</sup>. A $\beta$  monomers and fibrils did not inhibit long-term potentiation in the same paradigm, indicating that the inhibition is conformation-dependent. These low molecular mass oligomers run at a size that is not recognized by antibody A11, suggesting that they may be fibrillar oligomers. Whether there are other, more subtle strain variants within these classes of oligomers that uniquely define different strains of oligomers awaits to be determined by the development of monoclonal antibodies that can detect these differences or by determination of their actual structures. In the absence of more detailed structural information, conformation-dependent antibodies may provide a more rational means of classifying amyloid oligomers based on their underlying structural organization rather than on differences in size or sample preparation. This structure-based classification scheme may be more useful in comparing the toxic activity and pathological significance of oligomers. The availability of novel conformation-dependent antibodies that specifically recognize these assembly states also affords us a unique opportunity to clarify their roles in A $\beta$  fibril assembly and cellular toxicity, and they may ultimately be useful as therapeutic agents.

The abbreviations used are: A $\beta$ , amyloid- $\beta$ ; AD, Alzheimer disease; ADDLs, A $\beta$ -derived diffusible ligands.

## References

- [1] D. A. Kirschner, C. Abraham, and D. J. Selkoe, "X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation", Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 503-507 1986.
- [2] H. M. Wisniewski and R. D. Terry, "Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers", Prog. Neuropathol. Vol. 2, pp. 1-26, 1973.
- [3] J. Hardy and D. J. Selkoe, "The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics", Science, Vol. 297, pp. 353-356, 2002.
- [4] R. D. Terry, "The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis", J. Neuropathol. Exp. Neurol., Vol. 55, pp. 1023-1025, 1996.
- [5] M. A. Westerman, D. Cooper-Blacketer, A. Mariash, L. Kotilinek, T. Kawarabayashi, L. H. Younkin, G. A. Carlson, S. G. Younkin, and K. H. Ashe, J. Neurosci., "The relationship between A $\beta$  and memory in the Tg2576 mouse model of Alzheimer's disease", Vol. 22, pp. 1858-1867, 2002.
- [6] L. M. Billings, S. Oddo, K. N. Green, J. L. McGaugh, and F. M. Laferla, "Intraneuronal A $\beta$  causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice", Neuron, Vol. 45, pp. 675-688, 2005.
- [7] C. A. Mclean, R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Beyreuther, A. I. Bush, and C. L. Masters, "The redox chemistry of the Alzheimer's disease amyloid  $\beta$  peptide", Ann. Neurol., Vol. 46, pp. 860-866, 1999.
- [8] L. F. Lue, Y. M. Kuo, A. E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J. H. Kurth, R. E. Rydel, and J. Rogers, "Soluble amyloid  $\beta$  peptide concentration as a predictor of synaptic change in Alzheimer's disease", Am. J. Pathol., Vol. 155, pp. 853-862, 1999.
- [9] S. Baglioni, F. Casamenti, M. Bucciantini, L. M. Luheshi, N. Taddei, F. Chiti, C. M. Dobson, and M. Stefani, "Prefibrillar Amyloid Aggregates Could Be Generic Toxins in Higher Organisms", J. Neurosci., Vol. 26, pp. 8160-8167, 2006.
- [10] C. Haass and D. J. Selkoe, "Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide", Nat. Mol. Cell Biol., Vol. 8, pp. 101-112, 2007.
- [11] D. Burdick, B. Soreghan, M. Kwon, J. Kosmoski, M. Knauer, A. Henschen, J. Yates, C. Cotman, and C. Glabe, "A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured

- state", *J. Biol. Chem.*, Vol. 267, pp. 546-554, 1992.
- [12] C. Hilbich, B. Kisters-Woike, J. Reed, C. L. Masters, and K. Beyreuther, "The interaction of beta-amyloid protein fragment (12-28) with lipid environments", *J. Mol. Biol.*, Vol. 218, pp. 149-163, 1991.
- [13] B. Soreghan, J. Kosmoski, and C. Glabe, "Observation of metastable A $\beta$  amyloid protofibrils by atomic force microscopy", *J. Biol. Chem.*, Vol. 269, pp. 28551-28554, 1994.
- [14] W. Garzon-Rodriguez, M. Sepulveda-Becerra, S. Milton, and C. G. Glabe, "Amyloid  $\beta$ -peptide polymerization studied using fluorescence correlation spectroscopy", *J. Biol. Chem.*, Vol. 272, pp. 21037-21044, 1997.
- [15] D. M. Walsh, A. Lomakin, G. B. Benedek, M. M. Condron, and D. B. Teplow, "Amyloid  $\beta$ -protein fibrillogenesis structure and biological activity of protofibrillar intermediates", *J. Biol. Chem.*, Vol. 272, pp. 22364-22372, 1997.
- [16] J. D. Harper, S. S. Wong, C. M. Lieber, and P. T. Lansbury, "Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid- $\beta$  protein", *Chem. Biol.*, Vol. 4, pp. 119-125, 1997.
- [17] H. A. Lashuel, D. Hartley, B. M. Petre, T. Walz, and P. T. Lansbury, Jr, "Dissociation of amyloid fibrils of  $\alpha$ -synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities", *Nature*, Vol. 418, pp. 291, 2002.
- [18] M. Anguiano, R. J. Nowak, and P. T. Lansbury, Jr, "Membrane interaction of islet amyloid polypeptide", *Biochemistry*, Vol. 41, pp. 11338-11343, 2002.
- [19] A. Lomakin, D.B. Teplow, D. A. Kirschner, and G. B. Benedek, "Kinetic theory of fibrillogenesis of amyloid $\beta$ -protein", *Proc. Natl. Acad. Sci. USA*, Vol. 94, pp. 7942-7947, 1997.
- [20] M. P. Lambert, a. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. Morgan, I. Rozovsky, B. Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft, and W. L. Klein, "Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins", *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 6448-6453, 1998.
- [21] M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C. M. Dobson, and M. Stefani, "Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases", *Nature*, Vol. 416, pp. 507-511, 2002.
- [22] S. Lesne, M. T. Koh, L. Kotilinek, R. Kaye, C. G. Glabe, A. Yang, M. Gallagher, and K. H. Ashe, "A specific amyloid-beta protein assembly in the brain impairs memory", *Nature*, Vol. 440, pp. 352-357, 2006.
- [23] S. Barghorn, V. Nimmrich, A. Striebinger, C. Krantz, P. Keller, B. Janson, M. Bahr, M. Schmidt, R. S. Bitner, J. Harlan, E. Barlow, U. Ebert, and H. Hillen, "Artificial proteases toward catalytic drugs for amyloid diseases", *J. Neurochem.*, Vol. 95, pp. 834-847, 2005
- [24] D. Burdick, B. Soreghan, M. Kwon, J. Kosmoski, M. Knauer, A. Henschen, J. Yates, C. Cotman, and C. Glabe, "Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs", *J. Biol. Chem.*, Vol. 267, pp. 546-554, 1992.
- [25] P. T. Chang and Y. Su, "Protocol for qualitative analysis of the *in vitro* aggregation of synthetic beta-amyloid: A method applicable to the identification of substances that may have therapeutic efficacy for Alzheimer's disease", *Brain Res. Protoc.*, Vol. 6, pp. 6-12, 2000.
- [26] L. Giovannelli, C. Scali, M.S. Faussone-Pellegrini, G. Pepeu, and F. Casamenti, "Long-term changes in the aggregation state and toxic effects of beta-amyloid injected into the rat brain", *Neuroscience*, Vol. 87, pp. 349-357, 1998.
- [27] M. D. Kane, R. D. Schwarz, L. S. Pierre, M. D. Watson, M. R. Emmerling, P. A. Boxer, and G. K. Walker, "Inhibitors of V-Type ATPases, bafilomycin A1 and concanamycin A, protect against amyloidmediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction", *J. Neurochem.*, Vol. 72, pp. 1939-1947, 1999.
- [28] E. H. Koo and S. L. Squazzo, "Evidence that production and release of amyloid beta-protein involves the endocytic pathway", *J. Biol. Chem.*, Vol. 269, pp. 17386-17389, 1994.
- [29] M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft, and W.L. Klein, "Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins", *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 6448-6453, 1998.
- [30] G.A. MacGibbon, G.J. Cooper, and M. Dragunow, "Acute application of human amylin, unlike beta-amyloid peptides, kills undifferentiated PC12 cells

- by apoptosis”, *NeuroReport*, Vol. 8, pp. 3945-3950, 1997.
- [31] M.M. Pallitto, J. Ghanta, P. Heinzelman, L.L. Kiessling, and R.M. Murphy, “Recognition sequence design for peptidyl modulators of  $\beta$ -amyloid aggregation and toxicity”, *Biochemistry*, Vol. 38, pp. 3570-3578, 1999.
- [32] A. J. Patel, S. Gunasekera, A. Jen, and H. A. R de Silva, “ $\beta$ -Amyloid-mediated inhibition of redox activity (MTT reduction) is not an indicator of astroglial degeneration”, *NeuroReport*, Vol. 7, pp. 2026-2030, 1996.
- [33] C. J. Pike, A. J. Walencewicz, C. G. Glabe, and C. W. Cotman, “*In vitro* aging of beta-amyloid protein causes peptide aggregation and neurotoxicity”, *Brain Res.*, Vol. 563, pp. 311-314, 1991.
- [34] T. Pillot, B. Drouet, S. Queille, C. Labeur, J. Vandekerckhove, M. Rosseneu, M. Pincon-Raymond, and J. Chambaz, “The nonfibrillar amyloid peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain”, *J. Neurochem.*, Vol. 73, pp. 1626-1634, 1999.
- [35] G. Rimon, C. E. Bazenet, K. L. Philpott, and L. L. Rubin, “Increased surface phosphatidylserine is an early marker of neuronal apoptosis”, *J. Neurosci. Res.*, Vol. 48, pp. 563-570, 1997.
- [36] N. K. Robakis, N. Ramakrishna, G. Wolfe, and H.M. Wisniewski, “Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides”, *Proc. Natl. Acad. Sci. USA*, Vol. 84, pp. 4190-4194, 1987.
- [37] D. J. Selkoe, “Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease”, *Annu. Rev. Cell Biol.*, Vol. 10, pp. 373-403, 1994.
- [38] B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon, “Disaggregation of Alzheimer beta-amyloid by site-directed mAb”, *Proc. Natl. Acad. Sci. USA*, Vol. 94, pp. 4109-4112, 1997.
- [39] Y. Su, C. L. Chang, S. S. Lee, W. C. Chen, and C. F. Huang, “*In vitro* cytotoxic activity of 1-decarboxy-3-oxo-ceanothric acid in a human ovarian adenocarcinoma cell line”, *Res. Commun. Mol. Pathol. Pharmacol.*, Vol. 100, pp. 313-326, 1998.
- [40] R. Vassar, B. D. Bennett, S. Babu-Khan, S. Kahn, E. A. Mendiaz, P. Denis, D. B. Teplow, S. Ross, P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M.A. Jarosinski, A.L. Biere, E. Curran, T. Burgess, J. C. Louis, F. Collins, J. Treanor, G. Rogers, and M. Citron, “beta-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE”, *Science*, Vol. 286, pp. 735-741, 1999.
- [41] M. S. Wolfe, W. Xia, B. L. Ostaszewski, T. S. Diehl, W.T. Kimberly, and D. J. Selkoe, “Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity”, *Nature*, Vol. 398, pp. 513-517, 1999.
- [42] S. J. Wood, B. Maleeff, T. Hart, and R. Wetzel, “Physical morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer’s amyloid peptide Ab”, *J. Mol. Biol.*, Vol. 256, pp. 870-877, 1996.
- [43] T. Yamazaki, E. H. Koo, and D. J. Selkoe, “Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization”, *J. Cell Sci.*, Vol. 109, pp. 999-1008, 1996.
- [44] P. L. Whitney and C. Tanford, “Solubility of amino acids in aqueous urea solutions and its implications for the denaturation of proteins by urea”, *J. Biol. Chem.*, Vol. 237, pp. 1735-1737, 1962.
- [45] A. M. Catanzariti, T. A. Soboleva, D.A. Jans, P. G. Board, and R.T. Baker, “An efficient system for high-level expression and easy purification of authentic recombinant proteins”, *Protein Sci.*, Vol. 13, pp. 1331-1339, 2004.
- [46] C. Hyde, T. Johnson, D. Owen, M. Quibell, and R.C. Sheppard, “Some ‘difficult sequences’ made easy. A study of interchain association in solid-phase peptide synthesis”, *Int. J. Pept. Protein Res.*, Vol. 43, pp. 431-440, 1994.
- [47] C. S. Goldsbury, G. J. Cooper, K. N. Goldie, S. A. Muller, E.L. Saafi, W.T. Grujters, M.P. Misur, A. Engel, U. Aebi, and J. Kistler, “Polymorphic fibrillar assembly of human amylin”, *J. Struct. Biol.*, Vol. 119, pp. 17-27, 1997.
- [48] R. T. Baker, A. M. Catanzariti, Y. Karunasekara, T.A. Soboleva, R. Sharwood, S. Whitney, and P.G. Board, “Using deubiquitylating enzymes as research tools”, *Methods Enzymol.*, Vol. 398, pp. 540-554, 2005.
- [49] R. J. Jenny, K. G. Mann, and R. L. Lundblad, “A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa”, *Protein Expr. Purif.*, Vol. 31, pp. 1-11, 2003.
- [50] P. A. Nygren, S. Stahl, and M. Uhlen, “Engineering proteins to facilitate bioprocessing”, *Trends Biotechnol.*, Vol. 12, pp. 184-188, 1994.
- [51] A. K. Tickler, C. J. Barrow, and J. D. Wade, “Improved preparation of amyloid-beta peptides

- using DBU as Nalpha-Fmoc deprotection reagent", *J. Pept. Sci.*, Vol. 7, pp. 488-494, 2001.
- [52] D. T. Loo, A. Copani, C. J. Pike, E. R. Whittemore, A. J. Walencewicz, and C. W. Cotman, "Apoptosis is induced by  $\beta$ -amyloid in cultured central nervous system neurons", *Proc. Natl. Acad. Sci. USA*, Vol. 90, pp. 7951-7955, 1993.
- [53] K. J. Ivins and E. T. N. Bui, "Cotman CW.  $\beta$ -amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis", *Neurobiol. Dis.* Vol. 5, pp. 365-378, 1998.
- [54] C. Stadelmann, W. Bruck, C. Bancher, K. Jellinger, and H. Lassmann, "Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis", *J. Neuropathol. Exp. Neurol.*, Vol. 57, pp. 456-464, 1998.
- [55] P. Picone, R. Carrotta, G. Montana, M. R. Nobile, P. L. S. Biagio, and M. Di Carlo, "A $\beta$  oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures", *Biophysical J.*, Vol. 96, pp. 4200-4211, 2008.
- [56] C. M. Troy, S. A. Rabacchi, W. J. Friedman, T. F. Frappier, K. Brown, and M.L. Shelanski, "Caspase-2 mediates neuronal cell death induced by  $\beta$ -amyloid", *J. Neurosci.*, Vol. 20, pp. 1386-1392, 2000.
- [57] J. Harada and M. Sugimoto, "Activation of caspase-3 in  $\beta$ -amyloid induced apoptosis of cultured rat cortical neurons", *Brain Res.*, Vol. 842, pp. 311-323, 1999.
- [58] D. M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. Rowan, and D. J. Selkoe, "Intracerebroventricular administration of amyloid  $\beta$ -protein oligomers selectively increases dorsal hippocampal dialysate glutamate levels in the awake rat", *Nature*, Vol. 416, pp. 535-539, 2002.
- [59] J. P. Cleary, D. M. Walsh, J. J. Hofmeister, G. M. Shankar, M. A. Kuskowski, D. J. Selkoe, and K. H. Ashe, "Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function", *Nat. Neurosci.*, Vol. 8, pp. 79-84, 2005.
- [60] I. Klyubin, D. M. Walsh, C. A. Lemere, W. K. Cullen, G. M. Shankar, C. Betts, E. T. Spooner, K. Jiang, R. Anwyl, D. J. Selkoe, and M. J. Rowan, "Movement disorders: Neurodevelopment and neurobehavioural expression", *Nat. Med.*, Vol. 11, pp. 556-561, 2005.